19:14 , Mar 29, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers A five-protein signature could help predict the risk of ischemic stroke, MI and death from cardiovascular events in atherosclerosis patients. In serum samples from 282 patients and 403 healthy volunteers, a protein...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Clinical News

APPY1 regulatory update

Venaxis said FDA issued a not substantially equivalent response to the company’s 501(k) application for APPY1 to aid emergency room clinicians in identifying patients at low risk for appendicitis in individuals ages 2-20 with abdominal...
08:00 , Jan 19, 2015 |  BC Week In Review  |  Clinical News

APPY1 regulatory update

Venaxis submitted a response to FDA’s request for information related to its 510(k) application for APPY1 to aid emergency room clinicians in identifying patients at low risk for appendicitis in individuals ages 2-20 years with...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

APPY1 regulatory update

Venaxis said FDA provided the company with questions and requested information as part of the agency’s review of a 510(k) application for APPY1 to identify patients that are at low risk for appendicitis. The company...
07:00 , Jun 26, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer S100 calcium binding protein A8 (S100A8; calgranulin A; MRP8); S100A9 (calgranulin B; MRP14) In vitro and mouse studies identified myeloid-derived suppressor cell (MDSC)-depleting peptides...
07:00 , May 29, 2014 |  BC Innovations  |  Targets & Mechanisms

S100A9-clot not, bleed not

Although the new generation of antithrombotic drugs provides marked improvements over warfarin, they all still carry bleeding risk. S100 calcium binding protein A9 could represent a new target that, when blocked, prevents thrombosis without increasing...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Clinical News

APPY1 regulatory update

Venaxis submitted a 510(k) application to FDA for APPY1 to identify patients that are at low risk for appendicitis. The company is also seeking concurrent de novo classification of the test by FDA. FDA's de...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Clinical News

APPY1: Pivotal trial data

Top-line data from the U.S. pivotal CP-12 trial in 1,887 patients showed that Venaxis' APPY1 Test had an NPV of 97.3% for identifying patients at low risk for appendicitis. APPY1 Test also had 96.9% sensitivity...
23:39 , Mar 13, 2014 |  BC Extra  |  Clinical News

Venaxis reports pivotal data for appendicitis diagnostic

Venaxis Inc. (NASDAQ:APPY) said its APPY1 Test had a negative predictive value (NPV) of 97.3% for identifying patients at low risk for appendicitis in the pivotal U.S. CP-12 trial. The test also had 96.9% sensitivity...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Clinical News

APPY1: Completed pivotal trial enrollment

Venaxis completed enrollment of about 2,000 patients in a U.S. pivotal trial of APPY1. The trial enrolled patients ages 2-20 years that presented in the hospital emergency department with abdominal pain with suspicion of appendicitis...